Pharmacokinetic Analysis of Dynamic 18F-Fluoromisonidazole PET Data in Non–Small Cell Lung Cancer

Hypoxic tumors exhibit increased resistance to radiation, chemical, and immune therapies. 18F-fluoromisonidazole (18F-FMISO) PET is a noninvasive, quantitative imaging technique used to evaluate the magnitude and spatial distribution of tumor hypoxia. In this study, pharmacokinetic analysis (PKA) of 18F-FMISO dynamic PET extended to 3 h after injection is reported for the first time, to our knowledge, in stage III–IV non–small cell lung cancer (NSCLC) patients. Methods: Sixteen patients diagnosed with NSCLC underwent 2 PET/CT scans (1–3 d apart) before radiation therapy: a 3-min static 18F-FDG and a dynamic 18F-FMISO scan lasting 168 ± 15 min. The latter data were acquired in 3 serial PET/CT dynamic imaging sessions, registered with each other and analyzed using pharmacokinetic modeling software. PKA was performed using a 2-tissue, 3-compartment irreversible model, and kinetic parameters were estimated for the volumes of interest determined using coregistered 18F-FDG images for both the volume of interest–averaged and the voxelwise time–activity curves for each patient’s lesions, normal lung, and muscle. Results: We derived average values of 18F-FMISO kinetic parameters for NSCLC lesions as well as for normal lung and muscle. We also investigated the correlation between the trapping rate (k3) and delivery rate (K1), influx rate (Ki) constants, and tissue-to-blood activity concentration ratios (TBRs) for all tissues. Lesions had trapping rates 1.6 times larger, on average, than those of normal lung and 4.4 times larger than those in muscle. Additionally, for almost all cases, k3 and Ki had a significant strong correlation for all tissue types. The TBR–k3 correlation was less straightforward, showing a moderate to strong correlation for only 41% of lesions. Finally, K1–k3 voxelwise correlations for tumors were varied, but negative for 76% of lesions, globally exhibiting a weak inverse relationship (average R = −0.23 ± 0.39). However, both normal tissue types exhibited significant positive correlations for more than 60% of patients, with 41% having moderate to strong correlations (R > 0.5). Conclusion: All lesions showed distinct 18F-FMISO uptake. Variable 18F-FMISO delivery was observed across lesions, as indicated by the variable values of the kinetic rate constant K1. Except for 3 cases, some degree of hypoxia was apparent in all lesions based on their nonzero k3 values.

[1]  Tom W J Scheenen,et al.  IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. , 2006, International journal of radiation oncology, biology, physics.

[2]  S. Nehmeh,et al.  Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times , 2016, The Journal of Nuclear Medicine.

[3]  M. Graham,et al.  A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. , 1995, Medical physics.

[4]  Barbara Vanderstraeten,et al.  Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.

[5]  K. Krohn,et al.  Synthesis and characterization of congeners of misonidazole for imaging hypoxia. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  E. Milne Circulation of primary and metastatic pulmonary neoplasms. A postmortem microarteriographic study. , 1967, The American journal of roentgenology, radium therapy, and nuclear medicine.

[7]  F J Gilbert,et al.  Imaging tumour hypoxia with positron emission tomography , 2014, British Journal of Cancer.

[8]  Robert Tibshirani,et al.  An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Non–Small Cell Lung Cancers , 2006, Clinical Cancer Research.

[9]  Matthias Reimold,et al.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  Andrew Jackson,et al.  Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  S. Ametamey,et al.  Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  A. Heerschap,et al.  Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. , 2006, International journal of radiation oncology, biology, physics.

[13]  Brian F. Hutton,et al.  The importance of correction for tissue fraction effects in lung PET: preliminary findings , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  David L. Schwartz,et al.  Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer , 2006, Clinical Cancer Research.

[15]  K. Krohn,et al.  Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. , 1987, Radiation research.

[16]  M. Muzi,et al.  Imaging Hypoxia with 18F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis , 2016, The Journal of Nuclear Medicine.

[17]  T K Lewellen,et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.

[18]  A H Baydush,et al.  Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. , 2004, Medical physics.

[19]  C. Ling,et al.  New radiotherapy technologies. , 2003, Seminars in surgical oncology.

[20]  J. Eary,et al.  [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  Sadek Nehmeh,et al.  Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. , 2008, International journal of radiation oncology, biology, physics.

[22]  K L Lindsley,et al.  Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. , 1995, International journal of radiation oncology, biology, physics.

[23]  John L. Humm,et al.  Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging , 2008, Physics in medicine and biology.

[24]  A. Sweet-Cordero,et al.  Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics , 2010, Clinical Cancer Research.

[25]  J. D. Chapman,et al.  A marker for hypoxic cells in tumours with potential clinical applicability. , 1981, British Journal of Cancer.

[26]  B. Hutton,et al.  Improved correction for the tissue fraction effect in lung PET/CT imaging. , 2015, Physics in medicine and biology.

[27]  A. A. Lammertsma,et al.  On the use of image-derived input functions in oncological fluorine-18 fluorodeoxyglucose positron emission tomography studies , 1999, European Journal of Nuclear Medicine.

[28]  A. Kjaer,et al.  Kinetic modeling in PET imaging of hypoxia. , 2014, American journal of nuclear medicine and molecular imaging.

[29]  John L. Humm,et al.  Pharmacokinetic Analysis of Hypoxia 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer , 2010, Journal of Nuclear Medicine.

[30]  N. Gupta,et al.  Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. , 1998, Chest.

[31]  D. Brizel,et al.  Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  Daniela Thorwarth,et al.  A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia , 2005, Physics in medicine and biology.

[33]  H. Thierens,et al.  [18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.